杨冠军，2020年8月毕业于澳门大学中华医药研究院中药质量研究国家重点实验室生物医药专业，获哲学博士学位。2020年10月至今在宁波大学工作，任副研究员入选宁波大学首批王宽诚青年学者。中国药理学会会员，兼任Technology in Cancer Research & Treatment（2.8）和European Journal of Medical Research（4.2）副主编，BMC Immunology（IF = 3.0）, Journal of Tropical Medicine （IF = 2.2）和The Breast Journal（IF = 2.1）等杂志编委。多次受邀担任SCI收录期刊Frontiers in Immunology (IF=7.3)、和Cancers（IF = 5.2）等杂志客座编辑；此外还担任Heliyon (IF = 4.0) 顾问编委， Aging and Disease (IF = 7.4)、Chinese Medicine (IF = 4.9)和The Innovation (IF=32.1)等SCI收录杂志青年编委。目前主要从事炎症和癌症相关疾病的病理机制与药物调控的基础与应用方面的研究。已在Journal Hematolagy & Oncology (2篇)和Angewandte Chemie International Edition (1篇, 封底内页文章)、Acta Pharmaceutica Sinica B (1篇)和Medicinal Research Reviews (1篇)等高水平学术期刊上发表一作或通讯作者论文30余篇 (> 5分 22篇，含> 10分6篇），参与发表论文25篇，累计被引用1200余次。
王宽诚青年学者、浙江省优秀毕业生
(1)抗癌药物筛选及药理学机制研究。
(2)水产生物免疫与病害防控。
（1）高层次人才科研启动经费，“三阴乳腺癌靶向药物筛选与药理学机制研 究 (No. 421999392)”，主持。
（2）浙江省教育厅一般项目，“靶向 CDK9-cyclin T1 蛋白-蛋白互作治疗三阴乳腺癌的机制研究”，主持。
（3）横向项目：关于气片对过敏性哮喘急性期和长期稳定治疗疗效和机制探索，参与（顺序2/10）
（4）横向项目：LECT2治疗哮喘的应用前景分析，参与（顺序2/10）
（5）横向项目：BIFC基于的自噬调控剂筛选平台构建，参与（顺序2/10）
（1）Song YQ, Yang GJ*, Ma DL, Wang WH*, Leung CH*. The role and prospect of lysine-specific demethylases in drug resistance. Med Res Rev. 2023, 43:1438-1469. (IF: 13.3) 中科院双一区
（2）Yang GJ, Li CY, Tao F, Liu YJ, Zhu MH, Du Y, Fei CJ, She QS*, Chen J*. The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities. Genes Dis. 2023, 11(2): 645-663. (IF: 6.8) 中科院双一区
（3）Chen LJ, Xu XY, Zhong XD, Liu YJ, Zhu MH, Tao F, Li CY, She QS*, Yang GJ*, Chen J*. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy. Biorg Chem. 2023, 133: 106409. (IF: 5.1) 中科院双一区
（4）Yang GJ, Tao F, Zhong HJ*, Yang C*, and Chen J*. Targeting PGAM1 in Cancer: An emerging therapeutic opportunity. Eur J Med Chem. 2022, 244: 114798. (IF: 6.7) 中科院双一区
（5）Zhao D*, Zhang W, Yu S, Xia SL, Liu YN*, Yang GJ*. Light-mediated MOF-based nanotherapeutics for cancer diagnosis and therapy. J Nanobiotechnol. 2022, 20: 421. (IF: 10.2) 中科院双一区
（6）Cheng SS#, Qu YQ#, Wu J#, Yang GJ#, Liu H, Wang WH, Huang Q, Chen F, Li GD, Wong CY, Wong VKW*, Ma DL*, Leung CH*. Inhibition of the CDK9-Cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer. Acta Pharm Sin B. 2022, 13(2), 1390-1405. (IF: 14.5) 中科院双一区
（7）Yang GJ#, Wang WH#, Mok SWF, Wu C, Law BYK, Miao XM, Wu KJ, Zhong HJ, Wong CY, Wong VKW*, Ma DL*, Leung CH*. Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium (III) complex for triple-negative breast cancer therapy. Angew Chem Int Ed Engl. 2018, 57(40), 13091-13095. (Back inside cover, IF: 16.6) 中科院双一区
（8）Yang GJ, Zhu MH, Lu XJ, Liu YJ, Lu JF, Leung CH*, Ma DL*, Chen J*. The emerging role of KDM5A in human cancer. 2021. J Hematol Oncol. 14(1), 30. (IF: 28.5) 中科院双一区
（9）Cheng SS#, Yang GJ# (co-first author), Wang WH, Ma DL*, Leung CH*. The design and development of covalent protein-protein interaction inhibitors for cancer treatment. J Hematol Oncol. 2020, 13(1), 26. (IF: 28.5)
（10）Yang GJ#, Wang WH#, Lei PM, Leung CH*, Ma DL*. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy. Int J Biol Macromol. 2020, 164, 3204-3220. (IF: 8.2) 中科院双一区
（11）Yang GJ#, Wu J#, Ma DL*, Leung CH*, Chen J*. A Review on the Emerging Roles of Pyruvate Kinase M2 in Anti-leukemia Therapy. Int J Biol Macromol, 2021, 193, 1499-1506. (IF: 8.2)
（12）Yang GJ#, Wu J#, Miao L, Zhu MH, Zhou QJ, Lu XJ, Lu JF, Ma DL*, Leung CH*, Chen J*. Pharmacological inhibition of KDM5A for cancer treatment. Eur J Med Chem. 2021, 226, 113855. (IF: 6.7) 中科院双一区
（13）Yang GJ#, Zhong HJ #, Ko CN#, Wong SY#, Vellaisamy K, Ye M, Ma DL*, Leung CH*. Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells. Chem Commun. 2018, 54(20), 2463-2466. (Front Cover, IF: 4.9) 自然指数期刊
（14）Cheng SS#, Yang GJ# (co-first author), Wang WH#, Ma DL*, Leung CH*. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells. Genes Dis. 2022, 9(6), 1674-1688. (IF: 6.8)
（15）Yang GJ#, Song YQ#, Han QB*, Ma DL*, Leung CH*. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells. Biorg Chem. 2021, 114, 105158. (IF: 5.1)
无
本科生：《模式生物学》和《生理学》
博士生：《表观遗传学》
生物学，水产，渔业
担任本科生导师，指导本科生以第一作者发表SCI论文2篇，获得校SRIP项目3项。
无
